Massachusetts Financial Services Co. MA Sells 28,756 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Massachusetts Financial Services Co. MA reduced its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 29.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 69,415 shares of the company’s stock after selling 28,756 shares during the period. Massachusetts Financial Services Co. MA owned approximately 0.10% of Nurix Therapeutics worth $1,560,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of NRIX. Driehaus Capital Management LLC acquired a new position in Nurix Therapeutics in the 2nd quarter valued at $26,778,000. Candriam S.C.A. grew its holdings in shares of Nurix Therapeutics by 30.5% during the 2nd quarter. Candriam S.C.A. now owns 1,164,246 shares of the company’s stock valued at $24,297,000 after purchasing an additional 272,136 shares during the last quarter. Affinity Asset Advisors LLC grew its stake in shares of Nurix Therapeutics by 12.6% during the second quarter. Affinity Asset Advisors LLC now owns 912,000 shares of the company’s stock worth $19,033,000 after buying an additional 101,747 shares during the last quarter. Millennium Management LLC increased its holdings in Nurix Therapeutics by 60.2% in the 2nd quarter. Millennium Management LLC now owns 599,623 shares of the company’s stock worth $12,514,000 after purchasing an additional 225,374 shares in the last quarter. Finally, Samlyn Capital LLC acquired a new position in shares of Nurix Therapeutics in the second quarter valued at approximately $12,177,000.

Nurix Therapeutics Price Performance

Shares of NASDAQ NRIX opened at $21.23 on Thursday. The business’s fifty day moving average price is $24.17 and its 200-day moving average price is $21.70. Nurix Therapeutics, Inc. has a one year low of $5.68 and a one year high of $29.56. The stock has a market capitalization of $1.50 billion, a PE ratio of -7.30 and a beta of 2.20.

Nurix Therapeutics (NASDAQ:NRIX) last issued its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.67). The business had revenue of $12.59 million for the quarter, compared to analysts’ expectations of $13.85 million. Nurix Therapeutics had a negative net margin of 313.65% and a negative return on equity of 63.39%. As a group, equities analysts expect that Nurix Therapeutics, Inc. will post -2.81 EPS for the current fiscal year.

Insider Activity

In other Nurix Therapeutics news, CFO Houte Hans Van sold 3,546 shares of Nurix Therapeutics stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $24.28, for a total transaction of $86,096.88. Following the transaction, the chief financial officer now directly owns 33,724 shares of the company’s stock, valued at approximately $818,818.72. This trade represents a 9.51 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Christine Ring sold 5,760 shares of Nurix Therapeutics stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $22.23, for a total transaction of $128,044.80. Following the completion of the transaction, the insider now owns 24,592 shares in the company, valued at approximately $546,680.16. The trade was a 18.98 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 27,451 shares of company stock worth $663,160. 7.20% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. Oppenheimer increased their price objective on Nurix Therapeutics from $27.00 to $30.00 and gave the company an “outperform” rating in a report on Wednesday, September 4th. HC Wainwright lifted their price objective on shares of Nurix Therapeutics from $26.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Jefferies Financial Group started coverage on Nurix Therapeutics in a research note on Friday, October 11th. They set a “buy” rating and a $41.00 price target on the stock. UBS Group began coverage on shares of Nurix Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $35.00 price objective on the stock. Finally, Royal Bank of Canada dropped their target price on Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $29.40.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.